A Review of the Therapeutic Targeting of SCN9A and Nav1.7 for Pain Relief in Current Human Clinical Trials

Anton Dormer1 Research and Development, Pepvax, Inc, Silver Spring, MD, USACorrespondence[email protected]

Mahesh Narayanan1 Research and Development, Pepvax, Inc, Silver Spring, MD, USAView further author information

Jerome Schentag1 Research and Development, Pepvax, Inc, Silver Spring, MD, USAView further author information

Daniel Achinko1 Research and Development, Pepvax, Inc, Silver Spring, MD, USAView further author information

Elton Norman1 Research and Development, Pepvax, Inc, Silver Spring, MD, USAView further author information

James Kerrigan2 Research and Development, Navintus, Inc, Princeton, NJ, USAView further author information

Gary Jay2 Research and Development, Navintus, Inc, Princeton, NJ, USAView further author information

William Heydorn2 Research and Development, Navintus, Inc, Princeton, NJ, USAView further author information

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.